CG Oncology rises after brokerage lifts PT ahead of pivotal bladder cancer data

CG Oncology

07/04/2026 11:39

** Shares of biotech firm CG Oncology CGON.O rise 1% to $67.57 premarket

** Brokerage HC Wainwright raises price target on CGON to $100 from $80; reiterates "Buy"

** Brokerage says CGON’s lead therapy, cretostimogene, is being tested to reduce tumor recurrence in an early-stage form of bladder cancer that frequently returns after surgery

** Says recurrence rather than disease worsening is the main unmet need in this patient group, and that durable control would reduce repeat surgeries

** Brokerage adds late-stage trial needs to show sustained benefit beyond early timepoints to beat historical chemotherapy outcomes

** As of last close, stock up ~12% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))